Treatment of cancers using anti-NKG2A agents

Patent metadata

Field	Value
Publication number	US-11225519-B2
Application number	US-201916448016-A
Country	US
Kind code	B2
Filing date	Jun 21, 2019
Priority date	Oct 23, 2014
Publication date	Jan 18, 2022
Grant date	Jan 18, 2022

Abstract

The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

First claim

We claim:

1. A method of treating a head and neck squamous cell carcinoma (HNSCC) in an individual, the method comprising administering to the individual an antibody that binds a human NKG2A polypeptide and neutralizes the inhibitory activity of NKG2A.

2. The method of claim 1 , wherein the HNSCC is an oral cavity squamous cell carcinoma (OCSCC).

3. The method of claim 1 , wherein the HNSCC is an oropharyngeal tumor.

4. The method of claim 1 , wherein the HNSCC is a larynx tumor.

5. The method of claim 1 , wherein the HNSCC is a tumor of the hypopharynx.

6. The method of claim 1 , wherein the individual is human papilloma virus (HPV) positive.

7. The method of claim 1 , wherein the treatment or prevention of a HNSCC in an individual comprises:
a) determining whether HLA-E polypeptide is expressed by malignant cells from the individual having a HNSCC; and
b) upon a determination that malignant cells express HLA-E polypeptide at or above a reference level, administering to the individual an antibody that neutralizes the inhibitory activity of a human NKG2A polypeptide.

8. The method of claim 7 , wherein determining whether HLA-E polypeptide is expressed by malignant cells comprises obtaining from the individual a biological sample that comprises HNSCC cells, bringing said cells into contact with an antibody that binds a HLA-E polypeptide, and detecting cells that express HLA-E.

9. The method of claim 1 , wherein the antibody comprises an Fc-engineered constant region comprising an amino acid modification that reduces binding to a human Fcγ receptor.

10. The method of claim 1 , wherein the NKG2A antibody comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in SEQ ID NO: 2, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 7.

11. The method of claim 1 , wherein the anti-NKG2A antibody is administered several times at a dosing frequency from once about every week to once about per month.

12. A method of treating a HNSCC in a human patient, the method comprising administering to the patient an effective amount of each of: (a) an antibody that neutralizes the inhibitory activity of human NKG2A, and (b) an agent that binds the epidermal growth factor receptor (EGFR).

13. The method of claim 12 , wherein the agent that binds EGFR inhibits the biological activity of EGFR.

14. The method of claim 12 , wherein the agent that binds EGFR is an antibody that induces ADCC toward EGFR-expressing tumor cells.

15. The method of claim 12 , wherein the agent that binds EGFR is cetuximab.

16. The method of claim 12 , wherein the method comprises at least one administration cycle, wherein the cycle is a period of two weeks, wherein for each of the at least one cycles, one dose of the antibody that neutralizes the inhibitory activity of human NKG2A is administered and two doses of an antibody that binds EGFR are administered.

17. The method of claim 12 , wherein the method comprises at least one administration cycle, wherein the cycle is a period of two weeks, wherein for each of the at least one cycles, one dose of the antibody that neutralizes the inhibitory activity of human NKG2A are administered at a dose of 1-10 mg/kg and two doses of an antibody that binds EGFR are administered at a dose of 1-10 mg/kg.

18. The method of claim 12 , wherein the agent that binds EGFR is cetuximab and the NKG2A antibody comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in SEQ ID NO: 2, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 7.

Assignees

• Innate Pharma

Inventors

• Andre Pascale
• Blery Mathieu
• Soulas Caroline
• Wagtmann Nicolai

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title